ABOUT ARROW THERAPEUTICS

Arrow Therapeutics is a fully integrated pharmaceutical company, focused exclusively on the discovery and development of novel antiviral therapeutics. Established in 1998 and acquired by AstraZeneca in February 2007, Arrow currently has 58 employees working in state-of-the-art laboratory and office space in central London.

Within our focus on antiviral therapies, Arrow specialises in small molecule drugs with novel mechanisms of action. This focus has resulted in an exciting product pipeline - the lead compound RSV604 is a first-in-class small molecule antiviral against Respiratory Syncytial Virus (RSV) which was licensed to Novartis in June 2005 and is currently in Phase II trials. The most advanced of our Hepatitis C Virus (HCV) programmes is a Phase II NS5A inhibitor, the latest and potentially most promising new antiviral target in HCV. Earlier stage projects on Dengue Virus and Influenza are at the discovery stage.

Since its foundation, Arrow was well supported by a consortium of international investors who provided over £40 million in funding.

History

1998		Arrow established by 6 founding scientists, based in laboratories in Surrey. Seed funding provided by Unibio and founding scientists.
1999		Private shareholder funding round raises £1.5 million
2000		Series A venture capital funding round raises £11.1 million
2001		Arrow moves to state-of-the-art laboratories and office space in central London
2002		Series A venture capital funding round raises a further £7 million
2003		Arrow’s RSV compound enters Preclinical development
2004		Series B venture capital funding round raises over £23 million
2004		Arrow's RSV compound completes Phase I Trials
2005		Arrow's RSV compound enters Phase II Trials
2005		Arrow’s RSV compound licensed to Novartis
2006		Arrow selects Hepatitis C clinical candidate A-831
2006		Arrow's HCV compound A-831 enters Phase I
2007		Arrow selects further Hepatitis C clinical candidate A-689
2007		AstraZeneca acquires Arrow to broaden anti-infective capabilities
2008		AZD7295 enters Phase I clinical trials
2009		Proof of concept demonstrated for AZD7295
2009		RSV clinical candidate 2 and HCV clinical candidate 3 enter pre-clinical development
2010		Phase IIa clinical trials for AZD7295 to start in August 2010
2010		Polymerase programme to enter preclinical development in 3Q 2010

SEARCH THE SITE